Advertisement

Document › Details
OncoDNA S.A.. (4/27/16). "Press Release: OncoDNA Launches Its New Product OncoTRACE".
![]() |
Organisation | OncoDNA S.A. |
Group | OncoDNA (Group) | |
![]() |
Product | OncoTRACE testing services |
Product 2 | circulating tumor cell technology (CTC technology) | |
On 27 April 2016, OncoDNA has launched its new product called OncoTRACE. It’s the first test in the world which is really personalized. It uses a blood sample to monitor the progression of a patient's tumor and to rapidly assess treatment effectiveness. The purpose of this innovative, non-invasive test is to sequence circulating tumor DNA, that is genetic material which has escaped from the tumor and is found in the blood. OncoTRACE is the logical follow-up to OncoDEEP . During the first OncoDEEP analysis, the specific characteristics of the tumor, i.e. the mutations present, are identified. With OncoTRACE, a test is done on a blood sample and the mutations can be monitored. At the same time, the appearance of new mutations linked to treatment resistance can be tracked. The results obtained from this much less invasive technique can therefore monitor the evolution of the tumor, evaluate treatment effectiveness and hence identify any recurrence earlier than classic technologies can at present. The analysis can be done several times, depending on the clinical protocol chosen by the oncologist. Based on this new information OncoDNA can suggest other treatment options if necessary.
You will find the press articles and video via these links :
http://www.lalibre.be/economie/digital/l-ennemi-d-oncodna-c-est-le-cancer-5721d55d35702a22d6d5e22f#7957c
http://kanaalz.knack.be/nieuws/simpele-bloedtest-kan-evolutie-kanker-volgen/video-normal-696813.html
http://canalz.levif.be/news/oncodna-passe-a-la-vitesse-superieure-27-04-16/video-normal-494545.html?utm_content=buffer23a23&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
http://www.lecho.be/entreprises/pharma_biotechnologie/Un_test_sanguin_pour_suivre_l_efficacite_des_traitements_contre_les_cancers.9759779-3002.art?utm_medium=twitter&utm_source=dlvr.it
http://www.telesambre.be/traitement-du-cancer-une-premiere-mondiale-a-gosselies_d_17597.html
http://www.rtl.be/belrtl/Emission/sante-vous-bien-1275.aspx
http://www.rtbf.be/info/regions/detail_une-premiere-mondiale-dans-la-lutte-contre-le-cancer-lancee-a-charleroi?id=9281670
http://www.dhnet.be/regions/charleroi-centre/cancer-une-prise-de-sang-qui-en-dit-long-5720e20a35702a22d6cfe38c
http://www.lanouvellegazette.be/1559581/article/2016-04-27/gosselies-oncodna-presente-ses-methodes-de-traitement-et-de-suivi-du-cancer
Record changed: 2016-09-04 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for OncoDNA (Group)
- [1] OncoDNA S.A.. (11/17/20). "Press Release: Successful Friendly Takeover Bid Initiated by OncoDNA on IntegraGen’s Shares"....
- [2] OncoDNA S.A.. (7/9/20). "Press Release: Agreement to File a Friendly Takeover Bid Initiated by OncoDNA on IntegraGen to Acquire All Outstanding Shares at a Price of 2.20€ per Share". Gosselies & Evry....
- [3] OncoDNA S.A.. (2/14/20). "Press Release: OncoDNA Closes Successful Series B Investment Round". Gosselies....
- [4] IntegraGen S.A.. (11/12/18). "Press Release: IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers". Paris....
- [5] IntegraGen S.A.. (9/7/17). "Press Release: IntegraGen Announces CE-IVD Marking of miRpredX 31-3p Kit which Predicts Patient Response to anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer". Évry....
- [6] IntegraGen S.A.. (9/4/17). "Press Release: IntegraGen to Participate in the 17th Large & Midcap Event – Paris"....
- [7] IntegraGen S.A.. (4/21/17). "Press Release: IntegraGen Announces 2016 Annual Results". Évry....
- [8] IntegraGen S.A.. (3/8/17). "Press Release: Laboratoire Cerba Enters into Licensing Agreement with IntegraGen for the Commercialization of miR-31-3p Tumor Expression Test in France, Benelux, Middle East and Africa". Saint-Ouen l’Aumône & Évry....
- [9] – [GenomeWeb]. (2/23/17). "News: OncoDNA Acquires Spanish Cancer Genomics Firm BioSequence". New York....
- [10] IntegraGen S.A.. (2/3/17). "Press Release: IntegraGen Announces Successful Completion of a € 3.7 Million Capital Increase". Évry....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top